Clinical effectiveness of 1540nm non-ablative erbium laser in treatment of xanthelasma palpebrarum / 中华医学美学美容杂志

Objective Xanthelasma palpebrarum presents a therapeutic and aesthetic challenge because of its high visibility and frequent rate of recurrence with a wide variety of treatments.Many patients were disappointed by an initial unsuccessful treatment and fail to return for further therapy until the problem had become quite conspicuous.So a simple treatment with few side effects and good acceptance remains an important goal.Methods Eleven patients with xanthelasma lesions were treated with the 1540nm erbium:glass laser.We could see erythema and swell around the skin lesion immediately.It needed irradiate again after one month if there was residual lesion.The end point was the lesions completely removed.The therapeutic effect of 1540nm erbium laser,the adverse reaction and the satisfaction of patients were observed.Results All lesions were removed without hyperpigmentation or scarring.Conclusions The 1540 nm erbium:glass laser represents an effective means for treating xanthelasmas with few side effects and good acceptance.

1,550-nm Non-ablative Fractional Erbium-Glass Laser in the Treatment of Facial Inflammatory Acne: A Preliminary Study / 대한피부과학회지

BACKGROUND: Topical and systemic drugs have been successfully used in the treatment of acne. However, many people are concerned about the side effects of these medicines, especially the childbearing women. Recent reports demonstrated that sequential treatment with laser- and light-based devices lead to a clinical improvement in acne. Recently, we witnessed experienced a case of improvement of inflammatory acne lesions during the treatment of acne scars using a 1,550-nm non-ablative fractional erbium-glass laser. OBJECTIVE: This study was designed to investigate the efficacy and safety of 1,550-nm non-ablative fractional erbium-glass laser in the treatment of facial inflammatory acne vulgaris. METHODS: 11 patients with facial inflammatory acne vulgaris were recruited. These patients received three treatment sessions at a 3-week interval. Inflammatory lesions were counted before and after treatment. The sebum production was quantified using the Sebumeter(R). We graded the patients' self-assessment and the investigator's global assessment using a five-point scale used by the dermatologist. We also investigated the histological changes after the treatment sessions, and the adverse effects during the study. RESULTS: Treatment with 1,550-nm non-ablative fractional erbium-glass laser was well tolerated, resulting in the reduction of inflammatory lesions by 61% (p<0.05). However, the reduction in sebum production from the baseline was not statistically significant. Histopathologic examination of the inflammatory lesions showed a marked decrease in the dermal inflammatory cell infiltration around the perivascular and periappendageal area and the sebaceous glands became smaller after laser treatments. Side-effects were minimal, and were resolved within a few days. CONCLUSION: 1,550-nm non-ablative fractional erbium-glass laser was safe and effective for the treatment of facial inflammatory acne lesions.